Astellas and Kotobuki broaden label for Suglat in Japan

Astellas Pharma and Kotobuki Pharmaceutical have won approval in Japan for a new indication for Suglat (ipragliflozin L-Proline), to cover treatment of type 1 diabetes. The therapy, a a selective SGLT2 inhibitor, was approved for type 2 diabetes in Janua https://www.thepharmaletter.com/in-brief/brief-astellas-and-kotobuki-broaden-label-for-suglat-in-japan